Excerpt:

...

Drew Weissman, one of the winners of the 2023 Nobel Prize in Medicine, previously warned of the risks of vaccine-acquired immune deficiency syndrome (VAIDS) posed by mRNA shots.

This week, Weissman, along with fellow scientist Katalin Karikó, were awarded the 2023 Nobel Prize in Medicine for their role in developing the mRNA technology used by pharmaceutical companies.

Their work specifically underlies the Pfizer-BioNTech and Moderna COVID-19 vaccines.

The mRNA shots were rolled out for public use in late 2020.

However, Weissman has previously warned about the “non-trivial” side effects linked to the injections.

In a paper published as recently as 2018, Weissman warned that prior clinical trials of mRNA vaccines had produced results that were “more modest in humans than was expected based on animal models… and the side effects were not trivial.”

Those “side effects” include “moderate and in rare cases severe injection site or systemic reactions”.

Weissman’s paper in the peer-reviewed Nature Reviews Drug Discovery highlighted the health risk that the shots posed.

They warned that can cause VAIDS – a form of AIDS-like immunodeficiency.

Their chief safety concerns, which they said should be closely watched in future trials, were about local and systemic inflammation.

They also urged keeping tabs on the “expressed immunogen” and on any auto-reactive antibodies.

“A possible concern could be that some mRNA-based vaccine platforms induce potent type I interferon responses, which have been associated not only with inflammation but also potentially with autoimmunity,” they wrote.

“Thus, identification of individuals at an increased risk of autoimmune reactions before mRNA vaccination may allow reasonable precautions to be taken.”

Weissman also warned in the paper that the mRNA shots can cause blood clots.

The authors noted in the paper that extracellular RNA could contribute to edema, and cited a study that showed it “promoted blood coagulation and pathological thrombus formation.”

“Safety will therefore need continued evaluation as different mRNA modalities and delivery systems are utilized for the first time in humans and are tested in larger patient populations,” they warned in the paper, which was published in 2018.

...